Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 25, 2011 (rev. 1)

Premium

Selventa has selected John Tagliamonte to serve as senior vice president of corporate development.

In his new role, Tagliamonte will work on establishing strategic partnerships with global pharmaceutical and biotechnology companies.

Prior to joining Selventa (formerly GenStruct), Tagliamonte was vice president of business development at Anchor Therapeutics and led strategy and corporate development efforts at ImmunoGen. He has also held positions at Millipore, Laureate Pharma, and Johnson & Johnson.

Tagliamonte earned his BS from Tufts University and an MBA from Boston College.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.